What is the purpose of this trial?
The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in patients who are statin intolerant.
Ages: 18 years and older
Dates: 10/17/2017 - 12/31/2021
Last Updated: 10/19/2017
Study HIC#: 2000020628